Skip to main content
Signal8

RADNOSTIX INC (INIS) Form 10-Q — May 20, 2026

$INISForm 10-QFiled May 20, 2026, 2:36 PM ET0001437749-26-017906Original filing

Radnostix Inc. reported a 27% year-over-year revenue decline to $2.38 million for Q1 2026, driven by voluntary recalls of its Generic Sodium Iodide I-131 and Dibasic Sodium Phosphate Capsules, as well as a shutdown of its Cobalt-60 manufacturing hot cells for rehabilitation. The company posted a net loss of $1.35 million, significantly worse than the $112,694 loss in the prior year period, exacerbated by a $102,441 out-of-period accounting adjustment for stock-based compensation and increased operating expenses.

Key figures

Revenue
2378924
Total Debt
14541527
Revenue Yoy
-27
Cash Position
1347394
Gross Profit
1150948
Operating Expenses
2460980
Shares Outstanding
529130353
Duf6 Asset Sale Value
12500000
Out Of Period Adjustment
102441
Stock Based Compensation
244059
Series CPreferred Dividends
243780

Price after filing

1 day: -4.8%7 days: -6.0%30 days: -12.4%

Close on the filing date to close N calendar days later (from $0.08). Historical, not a forecast.

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.